Russia’s Epivaccorona vaccine will provide immunity against COVID-19 for approximately a year, the State Research Center of Virology and Biotechnology "Vector" informed.

"We expect that it (the vaccine - TASS) will provide immunity for a year," Tatyana Nepomnyashchikh, an official with the research center, said during a round table dedicated to COVID-19.

Also read: AstraZeneca: Vaccine may work against UK variant

On July, 24, 2020, the Vector State Research Center of Virology and Biotechnology received a Russian health ministry permit for clinical trials of its anti-coronavirus vaccine on volunteers. The first volunteer was inoculated on July 27. The vaccine’s clinical trials were completed on September 30. Russian President Vladimir Putin said on October 14 that the Vector-developed vaccine had received registration. On November 16, the health ministry issued a permit for post-registration trials of the vaccine on volunteers older than 60 and a permit for tests on 3,000 volunteers aged from 18 to 60 was issued on November 18.

Also read: Study finds 'Oxford vaccine' may reduce virus transmission